Chan Simon, Bhandari Mohit
Hamilton Health Sciences-General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada.
J Bone Joint Surg Am. 2007 Sep;89(9):1970-8. doi: 10.2106/JBJS.F.01591.
The Consolidated Standards of Reporting Trials statement for the reporting of randomized controlled trials has been limited by its applicability to surgical trials. In response, a Checklist to Evaluate a Report of a Nonpharmacological Trial was recently developed by the Consolidated Standards of Reporting Trials group to address reporting issues in surgical trials. We aimed (1) to apply the checklist for nonpharmacological therapies to orthopaedic randomized controlled trials across multiple journals from 2004 through 2005, and (2) to survey authors when methodological safeguards itemized in the checklist were not reported to determine whether they actually had been performed. We hypothesized that lack of reporting of a methodological safeguard did not necessarily mean it had not been conducted.
We searched for relevant orthopaedic randomized controlled trials across eight journals in the period from January 2004 through December 2005. We applied the Checklist to Evaluate a Report of a Nonpharmacological Trial to all eligible studies. We contacted authors to determine what methodological safeguards were actually used, especially when details remained unclear from the publication.
We included eighty-seven randomized controlled trials from eighty-five scientific reports. In assessing the randomized controlled trials with the checklist for nonpharmacological therapies, seventy-three studies (84%) had unclear reporting of treatment allocation concealment. Only seventeen studies (20%) mentioned surgeon skill or experience. The blinding of patients, ward staff, rehabilitation staff, clinical outcome assessors, and nonclinical outcome assessors was unclear in forty-eight (55%), sixty-three (72%), sixty-four (74%), forty (46%), and thirty-three studies (38%), respectively. Authors from forty-three randomized controlled trials responded to our survey. The results of the survey showed that 41% (95% confidence interval, 25% to 58%) of the trials had adequate allocation concealment when this had been unclear from the report. Although the surgical experience of the investigators was rarely reported, most authors (70%) acknowledged that they had defined "surgical expertise criteria" such as minimum case criteria, specialized training, and clinical performance. The survey also showed that 28% to 40% of the trials had blinding of relevant groups despite the fact that the reporting of such blinding had been unclear in the publications.
The quality of reporting in the orthopaedic literature was highly variable. Readers should not assume that bias-reducing safeguards that were not reported in a randomized controlled trial did not occur. Our study reinforces the need for the consistent use of a tool like the Checklist to Evaluate a Report of a Nonpharmacological Trial to assess the methodology of surgical trials.
用于报告随机对照试验的《报告试验的统一标准》(CONSORT声明)在应用于外科试验时存在局限性。作为回应,CONSORT小组最近制定了一份《非药物试验报告评估清单》,以解决外科试验中的报告问题。我们旨在:(1)将非药物治疗清单应用于2004年至2005年多家期刊上的骨科随机对照试验;(2)当清单中列出的方法学保障措施未被报告时,对作者进行调查,以确定这些措施是否实际实施。我们假设,方法学保障措施未被报告并不一定意味着未实施。
我们检索了2004年1月至2005年12月期间八本期刊上的相关骨科随机对照试验。我们将《非药物试验报告评估清单》应用于所有符合条件的研究。我们联系作者以确定实际使用了哪些方法学保障措施,尤其是当出版物中的细节仍不清楚时。
我们纳入了来自85份科学报告的87项随机对照试验。在用非药物治疗清单评估随机对照试验时,73项研究(84%)的治疗分配隐藏报告不清楚。只有17项研究(20%)提到了外科医生的技能或经验。患者、病房工作人员、康复工作人员、临床结局评估者和非临床结局评估者的盲法在48项(55%)、63项(72%)、64项(74%)、40项(46%)和33项研究(38%)中不清楚。43项随机对照试验的作者回复了我们的调查。调查结果显示,当报告不清楚时,41%(95%置信区间,25%至58%)的试验有充分的分配隐藏。尽管很少报告研究者的手术经验,但大多数作者(70%)承认他们已经定义了“手术专业标准”,如最低病例标准、专业培训和临床表现。调查还显示,尽管出版物中此类盲法的报告不清楚,但28%至40%的试验对相关组进行了盲法。
骨科文献的报告质量差异很大。读者不应假定随机对照试验中未报告的减少偏倚的保障措施未发生。我们的研究强化了持续使用像《非药物试验报告评估清单》这样的工具来评估外科试验方法学的必要性。